Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer have?
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer has 445 citations in the OpenAlex counts ScholarIQ stores.
When was Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer published?
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer has 2023 year in the ScholarIQ index.
What is the open-access status of Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer?
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer has green oa status in the ScholarIQ index.
What is the DOI of Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer?
The DOI for Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer is on the source record.
What is the PMID of Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer?
The PMID for Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer is on the source record.
What is the OpenAlex record for Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer?
The OpenAlex for Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer is on the source record.